Fig. 4

Efficacy of XL102 in-vivo AML model. In subcutaneous model, 2 million MOLM13 cells were injected in flank region. Ten days after establishing tumor, mice were randomized and treated with XL102 (60 mg/Kg/oral daily) and Cytarabine (20 mg/Kg/intraperitoneal daily) for 12 days. A Representative image of tumor from mice treated with vehicle control, Cytarabine and XL102 B Mean tumor weight (in grams) and mean tumor volume of mice treated with vehicle control, Cytarabine and XL102 (n = 9 in each group). C-D Determination of apoptosis and cell cycle markers from tumor excised from xenografts and the quantification of blots. For orthotopic model, after confirming the successful AML engraftment, mice were randomized into three groups and treated with XL102 (60 mg/Kg/oral daily) and Cytarabine (20 mg/Kg/intraperitoneal daily) for 12 days E Decrease in expression of hCD45 in bone marrow of treated animal groups in comparison to control. F Changes in spleen weight and splenic ratio. G H&E and immunohistochemistry staining of Ki67 and CC3 of spleen sections from vehicle or drug treated animals. Original magnification, 40X. H Kaplan–Meier curve showing overall survival of mice xenotransplanted with MOLM13 AML cells and treated with control, Cytarabine or XL102. Statistical significance was calculated using log-rank (Mantel–Cox) test (P = 0.0004; n = 6 per arm)